Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Fig. 4

Western blot analysis for expression of pAKT and survivin. a-b Signal from immunodetection of pAkt, Akt, survivin and β-actin as the internal control. c-d Intensity of pAKT normalized by Akt expression. e-f Intensity of survivin normalized by β-actin expression. M = mock transfected, PN = PN-transfected, error bar determined SEM, * = P-value < 0.05 and n.s. = not significant

Back to article page